MX2017015926A - Uso de derivados de bencimidazol para escape acido nocturno. - Google Patents

Uso de derivados de bencimidazol para escape acido nocturno.

Info

Publication number
MX2017015926A
MX2017015926A MX2017015926A MX2017015926A MX2017015926A MX 2017015926 A MX2017015926 A MX 2017015926A MX 2017015926 A MX2017015926 A MX 2017015926A MX 2017015926 A MX2017015926 A MX 2017015926A MX 2017015926 A MX2017015926 A MX 2017015926A
Authority
MX
Mexico
Prior art keywords
benzimidazole derivative
acid breakthrough
nocturnal acid
breakthrough
treating
Prior art date
Application number
MX2017015926A
Other languages
English (en)
Inventor
Nobuyuki Takahashi
Koizumi Shinichi
Tajimi Masaomi
Jin Lee Ha
Tae Kim Bong
Kim Hyun
Yeon NAM Ji
Eun Park Jie
Seog Song Geun
Young RYU Shin
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57504150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017015926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of MX2017015926A publication Critical patent/MX2017015926A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un uso de compuestos derivados de bencimidazol para la mejora y el tratamiento del escape ácido nocturno (EAN). Los compuestos derivados de bencimidazol pueden prevenir y tratar de forma más efectiva las enfermedades relacionadas con el ácido gástrico al mejorar y tratar eficazmente los sí­ntomas nocturnos del escape ácido nocturno.
MX2017015926A 2015-06-08 2016-06-08 Uso de derivados de bencimidazol para escape acido nocturno. MX2017015926A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172680P 2015-06-08 2015-06-08
PCT/KR2016/006072 WO2016200148A1 (ko) 2015-06-08 2016-06-08 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도

Publications (1)

Publication Number Publication Date
MX2017015926A true MX2017015926A (es) 2018-07-06

Family

ID=57504150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015926A MX2017015926A (es) 2015-06-08 2016-06-08 Uso de derivados de bencimidazol para escape acido nocturno.

Country Status (26)

Country Link
US (2) US10512635B2 (es)
EP (1) EP3305291B1 (es)
JP (1) JP6792269B2 (es)
KR (3) KR20160144927A (es)
CN (1) CN108012527A (es)
CL (1) CL2017003133A1 (es)
CY (1) CY1124590T1 (es)
DK (1) DK3305291T3 (es)
ES (1) ES2890481T3 (es)
HK (1) HK1252562A1 (es)
HR (1) HRP20211046T1 (es)
HU (1) HUE056322T2 (es)
IL (1) IL256127B (es)
LT (1) LT3305291T (es)
MA (1) MA41730B1 (es)
MX (1) MX2017015926A (es)
MY (1) MY197209A (es)
PH (1) PH12017502221A1 (es)
PL (1) PL3305291T3 (es)
PT (1) PT3305291T (es)
RS (1) RS62074B1 (es)
RU (1) RU2672248C1 (es)
SG (1) SG11201710006PA (es)
SI (1) SI3305291T1 (es)
TN (1) TN2017000510A1 (es)
WO (1) WO2016200148A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101960357B1 (ko) * 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR102262743B1 (ko) * 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
MX2021009893A (es) * 2019-02-18 2021-09-14 Hk Inno N Corp Composicion farmaceutica que comprende compuesto derivado de benzoimidazol.
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
US20220020481A1 (en) 2020-07-20 2022-01-20 Abbott Laboratories Digital pass verification systems and methods
KR102648315B1 (ko) * 2021-12-08 2024-03-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) * 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
ES2332534T3 (es) 2005-06-14 2010-02-08 Raqualia Pharma Inc Derivados de bencimidazol sustituidos con cromano como antagonistas de la bomba de acidos.
WO2007072146A1 (en) * 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
WO2008067037A2 (en) * 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008151927A2 (en) 2007-06-15 2008-12-18 Nycomed Gmbh 6-n-substituted benz imidazole derivatives as acid pump antagonists
PT2262790T (pt) 2008-03-10 2017-07-18 Takeda Pharmaceuticals Co Cristal de composto de benzimidazole
CN102470126A (zh) 2009-07-09 2012-05-23 拉夸里亚创药株式会社 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
RU2537140C1 (ru) * 2013-09-17 2014-12-27 Леонид Федосеевич Ляпустин Способ антихеликобактерной терапии желудка и двенадцатиперстной кишки

Also Published As

Publication number Publication date
KR20200002739A (ko) 2020-01-08
KR20180036931A (ko) 2018-04-10
IL256127B (en) 2021-04-29
US20180338954A1 (en) 2018-11-29
EP3305291A1 (en) 2018-04-11
US11033532B2 (en) 2021-06-15
RU2672248C1 (ru) 2018-11-13
EP3305291B1 (en) 2021-05-19
PL3305291T3 (pl) 2021-11-02
MA41730B1 (fr) 2019-03-29
US20200069652A1 (en) 2020-03-05
HRP20211046T1 (hr) 2021-10-01
MA41730A1 (fr) 2018-08-31
IL256127A (en) 2018-02-28
SI3305291T1 (sl) 2021-08-31
PT3305291T (pt) 2021-07-05
TN2017000510A1 (en) 2019-04-12
DK3305291T3 (da) 2021-06-28
EP3305291A4 (en) 2019-01-23
ES2890481T3 (es) 2022-01-20
CY1124590T1 (el) 2022-07-22
CL2017003133A1 (es) 2018-04-13
WO2016200148A1 (ko) 2016-12-15
JP6792269B2 (ja) 2020-11-25
CN108012527A (zh) 2018-05-08
MY197209A (en) 2023-06-01
RS62074B1 (sr) 2021-07-30
KR102061052B1 (ko) 2019-12-31
PH12017502221A1 (en) 2018-06-04
HUE056322T2 (hu) 2022-02-28
LT3305291T (lt) 2021-08-25
SG11201710006PA (en) 2018-01-30
HK1252562A1 (zh) 2019-05-31
JP2018516951A (ja) 2018-06-28
KR20160144927A (ko) 2016-12-19
US10512635B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
PH12017502221A1 (en) Use of benzimidazole derivatives for nocturnal acid breakthrough
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
ZA201701299B (en) Glycosidase inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
MX2018005696A (es) Tratamiento de la osteoartritis.
NZ730730A (en) Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
MY197698A (en) Oxysterols and methods of use thereof
MX2016002794A (es) Compuestos antiproliferativos.
TN2020000082A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12017500747B1 (en) Heterocyclic compound
PH12019502248A1 (en) Ip6k inhibitors
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
TN2018000157A1 (en) Sodium channel blocker
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
PH12015502652A1 (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: GLACEUM, INC.